


AMENDED CLAIM SET:

1. (cancelled).

2. (previously presented) A 1,2,4-benzothiadiazine derivative of the formula:



wherein

R³ represents cycloalkyl; and

R⁴ represents hydrogen; and

R⁵ represents hydrogen; and

R⁶ represents hydrogen or alkyl; and

R⁷ represents -SO₂-NR¹⁷R¹⁸, wherein R¹⁷ and R¹⁸ independently of each another represent hydrogen or alkyl, or R¹⁷ and R¹⁸ together with the nitrogen to which they are attached form a heterocyclic 3- to 8-membered ring structure, which ring structure is optionally substituted with alkyl; and

R⁸ represents hydrogen or alkyl.

3. – 7. (cancelled).

8. (previously presented) The 1,2,4-benzothiadiazine derivative of claim 2, wherein R⁷ represents -SO₂-NR¹⁷R¹⁸, wherein R¹⁷ and R¹⁸ independently represent hydrogen or alkyl.

9. (cancelled).

10. (currently amended) The 1,2,4-benzothiadiazine derivative of claim 2, wherein

R³ represents cycloalkyl; and

R⁴ represents H; and

R⁵ represents H; and

R⁶ represents hydrogen or alkyl; and

R⁷ represents -SO₂-NR¹⁷R¹⁸, wherein R¹⁷ and R¹⁸ independently represent hydrogen or alkyl, or R¹⁷ and R¹⁸ together with the nitrogen to which they are attached form a heterocyclic 3-to 8-membered ring structure, which ring structure is optionally substituted with alkyl; and

R⁸ represents alkyl.

11. (previously presented) The 1,2,4-benzothiadiazine derivative of claim 2, wherein R³ represents cyclopentyl or cyclohexyl.

12. (cancelled).

13. (cancelled).

14. (previously presented) The 1,2,4-benzothiadiazine derivative of claim 2, wherein R⁶ represents hydrogen or methyl.

15. (previously presented) The 1,2,4-benzothiadiazine derivative of claim 2, wherein R⁷ represents N,N-dimethylsulfamoyl, N,N-diethylsulfamoyl, or -SO₂-heterocyclic ring, wherein the heterocyclic ring is selected from the group of piperidine, pyrrolidine, 1,2,5,6-tetrahydropyridine, N-methylpiperazine, N-sulfonylmethyl-piperazine, and morpholine.

16. (cancelled).

17. (cancelled).

18. (withdrawn – currently amended) The 1,2,4-benzothiadiazine derivative of claim 2, wherein

R³ represents cyclohexyl; and
R⁷ represents N,N-dimethylsulfamoyl; and
R⁵, R⁴, R⁶, and R⁸ all represent hydrogen.

19. – 21. (cancelled).

22. (currently amended) The 1,2,4-benzothiadiazine derivative according to claim 2, said compound being:

3-Cyclohexyl-7-(N,N-diethylamino)sulfonyl-1,2,3,4-tetrahydro-1,2,4-benzothiadiazine-1,1-dioxide;

3-Cyclopropyl-7-piperidinosulfonyl-1,2,3,4-tetrahydro-1,2,4-benzothiadiazine-1,1-dioxide;

3-Cyclopentyl-7-piperidinosulfonyl-1,2,3,4-tetrahydro-1,2,4-benzothiadiazine-1,1-dioxide;

3-Cyclohexyl-7-piperidinosulfonyl-1,2,3,4-tetrahydro-1,2,4-benzothiadiazine-1,1-dioxide;

3-Cyclohexyl-7-(1',2',3',6'-tetrahydropiperidino)sulfonyl-1,2,3,4-tetrahydro-1,2,4-benzothiadiazine-1,1-dioxide;

3-Cyclohexyl-7-(4'-methylpiperazino)sulfonyl-1,2,3,4-tetrahydro-1,2,4-benzothiadiazine-1,1-dioxide;

3-Cyclohexyl-7-(4'-methylsulfonylpiperazino)sulfonyl-1,2,3,4-tetrahydro-1,2,4-benzothiadiazine-1,1-dioxide;

3-Cyclohexyl-7-morpholinosulfonyl-1,2,3,4-tetrahydro-1,2,4-benzothiadiazine-1,1-dioxide;

3-Cyclohexyl-8-methoxy-1,2,3,4-tetrahydro-1,2,4-benzothiadiazine-1,1-dioxide;

3-Cyclopentyl-6-methyl-7-piperidinosulfonyl-1,2,3,4-tetrahydro-1,2,4-benzothiadiazine-1,1-dioxide;

3-Cyclohexyl-6-methyl-7-morpholinosulfonyl-1,2,3,4-tetrahydro-1,2,4-benzothiadiazine-1,1-dioxide; or

3-Cyclohexyl-7-sulfamoyl-1,2,3,4-tetrahydro-1,2,4-benzothiadiazine-1,1-dioxide;

or a pharmaceutical acceptable salt thereof.

23. (cancelled).

24. (previously presented) A pharmaceutical composition comprising an effective amount of a 1,2,4-benzothiadiazine derivative according to claim 2, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable excipient, carrier or diluent.

25. – 27. (cancelled).

28. (withdrawn - currently amended) A method of treating a disorder or disease of a living animal body, including a human, which disorder or disease is responsive to modulation of the AMPA receptor complex of the central nervous system wherein the disorder or disease is selected from psychotic disorders, sexual dysfunction, intellectual impairment disorders, and depression, which method comprises administration of a therapeutically effective amount of a 1,2,4-benzothiadiazine derivative according to claim 2.

29. (cancelled).

30. (cancelled).

31. (cancelled).

32. (cancelled).

33. (previously presented) The 1,2,4-benzothiadiazine derivative of claim 22, which is 3-cyclopentyl-6-methyl-7-piperidinosulfonyl-1,2,3,4-tetrahydro-1,2,4-benzothiadiazine-1,1-dioxide; or a pharmaceutically acceptable salt thereof.